Entrada (TRDA) Officer Sells 1,760 Shares for RSU Tax Withholding

Rhea-AI Filing Summary

Sethuraman Natarajan, an officer at Entrada Therapeutics, Inc. (TRDA), reported a sale of 1,760 shares of the company's common stock on 09/02/2025 to satisfy tax withholding obligations from vested restricted stock units. The filing shows a weighted-average sale price of $5.4302, with individual trade prices ranging from $5.36 to $5.58. After the reported disposition, the reporting person beneficially owns 197,899 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing is a routine insider report documenting a tax-withholding sale tied to RSU vesting and does not state any other transactions or derivative holdings.

Positive

• Timely and transparent disclosure of the sale, including weighted-average price and execution range
• Sale explicitly tied to tax withholding for vested RSUs, indicating a routine compensation-related transaction

Negative

• Insider disposition of 1,760 shares reduced beneficial ownership, now reported at 197,899 shares

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding sale by an officer; timely disclosure and clear pricing range reduce governance concerns.

The sale of 1,760 shares to cover tax withholding related to vested RSUs is a common insider liquidity event and is explicitly disclosed as such in the Form 4. The filing provides the weighted-average price and the per-trade price range, which improves transparency. There is no indication in the form of opportunistic trading beyond tax-related disposition and no derivative positions reported. From a governance perspective, the timely filing and the stated purpose (tax withholding) are consistent with routine compensation settlements rather than signaling a change in executive confidence.

Securities Analyst

TL;DR: Insider sold a small block of shares at ~$5.43 average; ownership remains at 197,899 shares—transaction appears non-material to valuation.

The transaction shows a limited disposal of 1,760 shares at a weighted-average price of $5.4302, with individual executions between $5.36 and $5.58. The Form 4 documents the disposal as tax withholding for vested RSUs, which is a nondiscretionary reason for sale. The remaining beneficial ownership is reported as 197,899 shares. The disclosure is concise and supplies sufficient detail about pricing; the sale size relative to reported holdings is small and presented as administrative in nature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sethuraman Natarajan

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Research & Develop.

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		F		1,760(1)	D	$5.4302(2)	197,899	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the TRDA insider report on the Form 4?

The filing reports a sale of 1,760 shares on 09/02/2025 by Sethuraman Natarajan.

Why were the shares sold according to the Form 4 for TRDA?

The sale was made to cover tax withholding obligations arising from the vesting of previously granted RSUs.

At what price were the TRDA shares sold?

The weighted-average price was $5.4302; individual transactions ranged from $5.36 to $5.58.

How many TRDA shares does the reporting person own after the transaction?

After the reported sale, the reporting person beneficially owns 197,899 shares.

Who is the reporting person and what is their role at Entrada Therapeutics (TRDA)?

The reporting person is Sethuraman Natarajan, listed as President, Research & Develop. and an officer of the issuer.